In order to investigate the possibility of SHT as therapeutic for the treatment of atopic dermatitis (AD), cytotoxicity, anti-oxidant activity, modulatory and suppression activities of SHT were tested. 90% or higher cell viability was observed in all tested groups from 25 to 200 ug/ml using Raw 264.7 cells. SHT showed dose-dependent DPPH scavenging activity, with more than 80% scavenging activities at 400 and 800 ug/ml concentrations. SHT showed dose-dependent suppression activity of ROS production, especially at 200 ug/ml of 57.4%. SHT decreased NO production activity dose dependently, expecially at 200 ug/ml of 28.8%. IL-$1{eta}$, IL-6, MCP-1, TNF-${alpha}$ production rate were decreased by 45.7%, 15.5%, 8.9%, 16.5% respectively when Raw 264.7 cells were treated with LPS and with SHT of 200 ug/ml. However, only IL-6 and TNF-${alpha}$ showed significant changes. The results above indicate that SHT significantly reduces the effect of oxidative and inflammatory cytokines. The use of SHT in dermatitis can be widely suggested.